Depo-Provera Warning Label Controversy

Publish Date : 11/13/2024

Litigation involving Depo-Provera, a contraceptive injection, is intensifying due to claims its U.S. warning labels lack key safety information included in other countries. The lawsuits argue the U.S. label fails to mention the increased risk of developing intracranial meningiomas—brain tumors warned about in both European and Canadian Depo-Provera labels.

The lawsuits cite a recent British Medical Journal (BMJ) study indicating long-term Depo-Provera users may be over five times more likely to develop meningiomas than average. Plaintiffs allege experiencing severe symptoms such as headaches, memory loss, and vision issues, which led to tumor diagnoses.

Plaintiffs accuse manufacturers Pfizer and Viatris of negligence for not including the tumor risk on U.S. labels, despite warnings on international labels. With over 70 million Depo-Provera users worldwide in 2019, awareness of potential risks is growing, and new cases are being accepted as litigation expands.

McSweeney / Langevin is providing legal advice and representation to individuals harmed by Depo-Provera.